Skip to main content
Figure 2 | BMC Clinical Pharmacology

Figure 2

From: No relevant cardiac, pharmacokinetic or safety interactions between roflumilast and inhaled formoterol in healthy subjects: an open-label, randomised, actively controlled study

Figure 2

Time course of the geometric mean (68% range) plasma concentrations of roflumilast N-oxide (linear scale). R alone: roflumilast 500 μg once daily at steady state (Regimen A: Day 11; n = 12); RF: roflumilast 500 μg once daily and formoterol 24 μg twice daily at steady state (Regimen A: Day 18; n = 12); FR: formoterol 24 μg twice daily and roflumilast 500 μg once daily at steady state (Regimen B: Day 18; n = 12).

Back to article page

BMC Clinical Pharmacology

ISSN: 1472-6904